Free Newsletter
Idaho latest to sue over Zyprexa
Idaho has joined the queue of states--and unions and other third-party payers--that are suing Eli Lilly over Zyprexa marketing. Like the other plaintiffs, Idaho alleges that Lilly illegally marketed Zyprexa for a laundry list of off-label uses, including depression, insomnia, separation anxiety, phobic disorders and so on.
And like the others, Idaho doesn't just want to recoup its costs for the drug itself, but for "the effects of the drug, the long-term treatment of people who are diabetic or severely obese now," the state's deputy attorney general Brett DeLange told the Idaho Statesman. As you know, Lilly has issued warnings about the drug's links to weight gain and diabetes--but Lilly has also been accused of failing to warn of those side effects as soon as it knew about them.
Recently, Lilly agreed to pay the State of Alaska $15 million to settle the first Zyprexa case brought to trial. Now the company is fighting to keep some documents in that case under court seal. And Lilly is reportedly negotiating with the feds to settle a number of Zyprexa claims. Stay tuned.
- check out the story in the Statesman
- read the Pharmalot item
Related Articles:
FDA nixes long-acting Zyprexa
Did Lilly chief support off-label promos?
Former FDAer: Lilly hid risks for profit
Lilly strengthens Zyprexa warnings
Study: 86% of docs cut Zyprexa use
Zyprexa - Top 10 Warnings and Recalls
Comments
Zyprexa has generated a lot of bad press for Eli Lilly and they still have unresolved Zyprexa settlement claims.
Eli Lilly is 'reaping the whirlwind' for aggressive marketing of Zyprexa that has caused suffering and deaths.
Zyprexa is being avoided by doctors they aren't prescribing it for new patients at all anymore.
--
Daniel Haszard 4 year Zyprexa patient who got diabetes from it.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: